Prevalence, clinical manifestations, and treatment of esophageal inlet patch
1Department of Gastroenterology, KTO Karatay Üniversitesi Medicana Affiliye Hastanesi, Konya, Türkiye
2Department of General Surgery, KTO Karatay Üniversitesi Medicana Affiliye Hastanesi, Konya, Türkiye
Keywords: Dysphagia, inlet patch, optic chromoendoscopy, proton pump inhibitors.
Objectives: This study aimed to evaluate the prevalence, symptoms, and treatment of inlet patch (IP) in light of the literature.
Materials and methods: Between July 2020 and January 2022, among the 1,926 patients, a total of 48 patients (21 males, 27 females; mean age: 41.1±14.2 years; range, 18 to 82 years) who underwent esophagogastroduodenoscopy were included in the study. After defining the IP, the size of the IP was measured using an endoscope shaft. Following measurement, biopsy specimens were taken and the type of gastric mucosa and the presence of Helicobacter pylori in IP were evaluated.
Results: The mean IP diameter was 8.96±5.8 mm (range, 3-30 mm), with a maximum of two patches in the same case. Fourteen (29.2%) of the patients with IP were symptomatic. Of the symptomatic patients, eight (57.1%) were male and six (42.9%) were female. The most common presenting symptom was dysphagia (18.8%). The biopsies taken from the IP mucosa revealed that the most frequently detected mucosal type was oxyntic and 12 (25%) patients were positive for Helicobacter pylori.
Conclusion: Patients presenting with dysphagia, globus sensation, unexplained chronic cough, and painful swallowing should be carefully examined for cervical esophageal IP. Sedating the patients and evaluating the esophagus with optical chromoendoscopy, if possible, will improve the detection rate of IPs. Proton pump inhibitors may be a good option for symptomatic patients.
Cite this article as: Avcı E, Ay S. Prevalence, clinical manifestations, and treatment of esophageal inlet patch. D J Med Sci 2022;8(3):102-107.
The study protocol was approved by the Konya Medicana Hospital Ethics Committee (date: 28.01.2022, no: 2022/01). The study was conducted in accordance with the principles of the Declaration of Helsinki.
A written informed consent was obtained from each patient.
Data Sharing Statement:
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Idea/concept: E.A., S.A.; Design, control/supervision: E.A., S.A.; Data collecting and/or processing: E.A., S.A.; Analysis and/or interpretation: E.A., S.A.; Literature review: E.A., S.A.; Writing the article: E.A., S.A.; Critical Review: E.A., S.A.; Materials: E.A., S.A.
The authors declared no conflicts of interest with respect to the authorship and/ or publication of this article.
The authors received no financial support for the research and/or authorship of this article.